請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64295
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李明學 | |
dc.contributor.author | Hsin-Yun Wang | en |
dc.contributor.author | 王欣韻 | zh_TW |
dc.date.accessioned | 2021-06-16T17:39:16Z | - |
dc.date.available | 2015-09-19 | |
dc.date.copyright | 2012-09-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-15 | |
dc.identifier.citation | Agarwal, R. (2000). Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60, 1051-1059.
Arora, P., Ricks, T. K., and Trejo, J. (2007). Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. Journal of Cell Science 120, 921-928. Benaud, C., Dickson, R. B., and Lin, C. Y. (2001). Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem 268, 1439-1447. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2, 737-744. Bocheva, G., Rattenholl, A., Kempkes, C., Goerge, T., Lin, C.-Y., D'Andrea, M. R., Stander, S., and Steinhoff, M. (2009). Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer. J Invest Dermatol 129, 1816-1823. Bugge, T. H., Antalis, T. M., and Wu, Q. (2009). Type II transmembrane serine proteases. J Biol Chem 284, 23177-23181. Chattopadhyay, S., and Shubayev, V. I. (2009). MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway. Glia 57, 1316-1325. Cho, E. G., Schwartz, R. H., and Kim, M. G. (2005). Shedding of membrane epithin is blocked without LDLRA4 and its protease activation site. Biochem Biophys Res Commun 327, 328-334. Cohen, M., Meisser, A., Haenggeli, L., and Bischof, P. (2006). Involvement of MAPK pathway in TNF-α-induced MMP-9 expression in human trophoblastic cells. Molecular Human Reproduction 12, 225-232. Corbel, M., Belleguic, C., Boichot, E., and Lagente, V. (2002). Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biology and Toxicology 18, 51-61. Coussens, L. M., Tinkle, C. L., Hanahan, D., and Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490. Coussens, L. M., and Werb, Z. (1996). Matrix metalloproteinases and the development of cancer. Chem Biol 3, 895-904. Cowden Dahl, K. D., Symowicz, J., Ning, Y., Gutierrez, E., Fishman, D. A., Adley, B. P., Stack, M. S., and Hudson, L. G. (2008). Matrix Metalloproteinase 9 Is a Mediator of Epidermal Growth Factor–Dependent E-Cadherin Loss in Ovarian Carcinoma Cells. Cancer Research 68, 4606-4613. Denmeade, S. R., and Isaacs, J. T. (2002). A history of prostate cancer treatment. Nat Rev Cancer 2, 389-396. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826. Ding, K. F., Sun, L. F., Ge, W. T., Hu, H. G., Zhang, S. Z., and Zheng, S. (2005). Effect of SNC19/ST14 gene overexpression on invasion of colorectal cancer cells. World J Gastroenterol 11, 5651-5654. Duffy, M. J., McGowan, P. M., and Gallagher, W. M. (2008). Cancer invasion and metastasis: changing views. J Pathol 214, 283-293. Egeblad, M., and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174. Engsig, M. T., Chen, Q.-J., Vu, T. H., Pedersen, A.-C., Therkidsen, B., Lund, L. R., Henriksen, K., Lenhard, T., Foged, N. T., Werb, Z., and Delaissé, J.-M. (2000). Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor Are Essential for Osteoclast Recruitment into Developing Long Bones. The Journal of Cell Biology 151, 879-890. Fan, B., Wu, T. D., Li, W., and Kirchhofer, D. (2005). Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin. J Biol Chem 280, 34513-34520. Friedrich, R., Fuentes-Prior, P., Ong, E., Coombs, G., Hunter, M., Oehler, R., Pierson, D., Gonzalez, R., Huber, R., Bode, W., and Madison, E. L. (2002). Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J Biol Chem 277, 2160-2168. Galkin, A. V., Mullen, L., Fox, W. D., Brown, J., Duncan, D., Moreno, O., Madison, E. L., and Agus, D. B. (2004). CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. The Prostate 61, 228-235. Gross, J., and Lapiere, C. M. (1962). Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A 48, 1014-1022. Haibo, Z., Guoping, C., Jingyuan, D., Zhidao, X., Lan, W., and Tongbo, Z. (1997). Expression of matrix metalloproteinase-9 mRNA in osteoporotic bone tissues. Journal of Huazhong University of Science and Technology -- Medical Sciences -- 17, 28-31. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70. Hooper, J. D., Clements, J. A., Quigley, J. P., and Antalis, T. M. (2001). Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 276, 857-860. Hua, J., and Muschel, R. J. (1996). Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 56, 5279-5284. Ihara, S., Miyoshi, E., Nakahara, S., Sakiyama, H., Ihara, H., Akinaga, A., Honke, K., Dickson, R. B., Lin, C.-Y., and Taniguchi, N. (2004). Addition of β1-6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin. Glycobiology 14, 139-146. Ingraham, C. A., Park, G. C., Makarenkova, H. P., and Crossin, K. L. (2011). Matrix Metalloproteinase (MMP)-9 Induced by Wnt Signaling Increases the Proliferation and Migration of Embryonic Neural Stem Cells at Low O2 Levels. Journal of Biological Chemistry 286, 17649-17657. Itoh, T., Tanioka, M., Matsuda, H., Nishimoto, H., Yoshioka, T., Suzuki, R., and Uehira, M. (1999). Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 17, 177-181. Jin, J. S., Chen, A., Hsieh, D. S., Yao, C. W., Cheng, M. F., and Lin, Y. F. (2006a). Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol 14, 65-72. Jin, X., Yagi, M., Akiyama, N., Hirosaki, T., Higashi, S., Lin, C.-Y., Dickson, R. B., Kitamura, H., and Miyazaki, K. (2006b). Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Science 97, 1327-1334. Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F., and Jones, L. W. (1979). Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17, 16-23. Kang, J. Y., Dolled-Filhart, M., Ocal, I. T., Singh, B., Lin, C. Y., Dickson, R. B., Rimm, D. L., and Camp, R. L. (2003). Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63, 1101-1105. Kessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell 141, 52-67. Kim, C., Cho, Y., Kang, C. H., Kim, M. G., Lee, H., Cho, E. G., and Park, D. (2005). Filamin is essential for shedding of the transmembrane serine protease, epithin. EMBO Rep 6, 1045-1051. Kirchhofer, D., Peek, M., Lipari, M. T., Billeci, K., Fan, B., and Moran, P. (2005). Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 579, 1945-1950. Kiyomiya, K., Lee, M. S., Tseng, I. C., Zuo, H., Barndt, R. J., Johnson, M. D., Dickson, R. B., and Lin, C. Y. (2006). Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. American journal of physiology 291, C40-49. Kojima, K., Tsuzuki, S., Fushiki, T., and Inouye, K. (2009). Role of the stem domain of matriptase in the interaction with its physiological inhibitor, hepatocyte growth factor activator inhibitor type I. J Biochem 145, 783-790. Lee, M. S. (2006). Matrix-Degrading Type II Transmembrane Serine Protease Matriptase: Its Role in Cancer Development and Malignancy. Journal of Cancer Molecules 2, 8. Lee, S. L., Dickson, R. B., and Lin, C. Y. (2000). Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275, 36720-36725. Lin, C. Y., Anders, J., Johnson, M., and Dickson, R. B. (1999a). Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. The Journal of biological chemistry 274, 18237-18242. Lin, C. Y., Anders, J., Johnson, M., Sang, Q. A., and Dickson, R. B. (1999b). Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. The Journal of biological chemistry 274, 18231-18236. Lin, C. Y., Wang, J. K., Torri, J., Dou, L., Sang, Q. A., and Dickson, R. B. (1997). Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem 272, 9147-9152. List, K., Haudenschild, C. C., Szabo, R., Chen, W., Wahl, S. M., Swaim, W., Engelholm, L. H., Behrendt, N., and Bugge, T. H. (2002). Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21, 3765-3779. List, K., Kosa, P., Szabo, R., Bey, A. L., Wang, C. B., Molinolo, A., and Bugge, T. H. (2009). Epithelial Integrity Is Maintained by a Matriptase-Dependent Proteolytic Pathway. American Journal of Pathology 175, 1453-1463. List, K., Szabo, R., Molinolo, A., Nielsen, B. S., and Bugge, T. H. (2006). Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol 168, 1513-1525. List, K., Szabo, R., Molinolo, A., Sriuranpong, V., Redeye, V., Murdock, T., Burke, B., Nielsen, B. S., Gutkind, J. S., and Bugge, T. H. (2005). Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 19, 1934-1950. List, K., Szabo, R., Wertz, P. W., Segre, J., Haudenschild, C. C., Kim, S. Y., and Bugge, T. H. (2003). Loss of proteolytically processed filaggrin caused by epidermal deletion of matriptase/MT-SP1. Journal of Cell Biology 163, 901-910. MacDougall, J. R., and Matrisian, L. M. (1995). Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer and Metastasis Reviews 14, 351-362. Masson, R., Lefebvre, O., Noel, A., Fahime, M. E., Chenard, M. P., Wendling, C., Kebers, F., LeMeur, M., Dierich, A., Foidart, J. M., et al. (1998). In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 140, 1535-1541. Menashi, S., Fridman, R., Desrivieres, S., Lu, H., Legrand, Y., and Soria, C. (1994). Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein. Ann N Y Acad Sci 732, 466-468. Mendes, O., Kim, H.-T., and Stoica, G. (2005). Expression of MMP2, MMP9 and MMP3 in Breast Cancer Brain Metastasis in a Rat Model. Clinical and Experimental Metastasis 22, 237-246. Miyake, Y., Yasumoto, M., Tsuzuki, S., Fushiki, T., and Inouye, K. (2009). Activation of a membrane-bound serine protease matriptase on the cell surface. J Biochem 146, 273-282. Miyamoto, H., Altuwaijri, S., Cai, Y., Messing, E. M., and Chang, C. (2005). Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog 44, 1-10. Nagase, H., and Woessner, J. F., Jr. (1999). Matrix metalloproteinases. J Biol Chem 274, 21491-21494. Nalla, A. K., Gorantla, B., Gondi, C. S., Lakka, S. S., and Rao, J. S. (2010). Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther 17, 599-613. Netzel-Arnett, S., Currie, B. M., Szabo, R., Lin, C. Y., Chen, L. M., Chai, K. X., Antalis, T. M., Bugge, T. H., and List, K. (2006). Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem 281, 32941-32945. Noe, V., Fingleton, B., Jacobs, K., Crawford, H. C., Vermeulen, S., Steelant, W., Bruyneel, E., Matrisian, L. M., and Mareel, M. (2001). Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114, 111-118. Oberst, M. D., Chen, L. Y., Kiyomiya, K., Williams, C. A., Lee, M. S., Johnson, M. D., Dickson, R. B., and Lin, C. Y. (2005). HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol 289, C462-470. Oberst, M. D., Singh, B., Ozdemirli, M., Dickson, R. B., Johnson, M. D., and Lin, C. Y. (2003a). Characterization of matriptase expression in normal human tissues. J Histochem Cytochem 51, 1017-1025. Oberst, M. D., Williams, C. A., Dickson, R. B., Johnson, M. D., and Lin, C. Y. (2003b). The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 278, 26773-26779. Ogata, Y., Enghild, J. J., and Nagase, H. (1992). Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267, 3581-3584. Okada, Y., Gonoji, Y., Naka, K., Tomita, K., Nakanishi, I., Iwata, K., Yamashita, K., and Hayakawa, T. (1992). Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 267, 21712-21719. Page-McCaw, A., Ewald, A. J., and Werb, Z. (2007). Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8, 221-233. Parks, W. C., Wilson, C. L., and Lopez-Boado, Y. S. (2004). Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4, 617-629. Peschon, J. J., Slack, J. L., Reddy, P., Stocking, K. L., Sunnarborg, S. W., Lee, D. C., Russell, W. E., Castner, B. J., Johnson, R. S., Fitzner, J. N., et al. (1998). An essential role for ectodomain shedding in mammalian development. Science 282, 1281-1284. Radisky, L. S. O. a. D. C. (2008). Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clinical and Experimental Metastasis 25, 8. Rao, J. S., Gondi, C., Chetty, C., Chittivelu, S., Joseph, P. A., and Lakka, S. S. (2005). Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non–small cell lung cancer cells. Molecular Cancer Therapeutics 4, 1399-1408. Riddick, A. C., Shukla, C. J., Pennington, C. J., Bass, R., Nuttall, R. K., Hogan, A., Sethia, K. K., Ellis, V., Collins, A. T., Maitland, N. J., et al. (2005). Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 92, 2171-2180. Saleem, M., Adhami, V. M., Zhong, W., Longley, B. J., Lin, C. Y., Dickson, R. B., Reagan-Shaw, S., Jarrard, D. F., and Mukhtar, H. (2006). A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15, 217-227. Santin, A. D., Zhan, F., Bellone, S., Palmieri, M., Cane, S., Bignotti, E., Anfossi, S., Gokden, M., Dunn, D., Roman, J. J., et al. (2004). Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112, 14-25. Satomi, S., Yamasaki, Y., Tsuzuki, S., Hitomi, Y., Iwanaga, T., and Fushiki, T. (2001). A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem Biophys Res Commun 287, 995-1002. Sehgal, G., Hua, J., Bernhard, E. J., Sehgal, I., Thompson, T. C., and Muschel, R. J. (1998). Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol 152, 591-596. Shi, Y. E., Torri, J., Yieh, L., Wellstein, A., Lippman, M. E., and Dickson, R. B. (1993). Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 53, 1409-1415. Shim, Y.-J., Kang, B.-H., Jeon, H.-S., Park, I.-S., Lee, K.-U., Lee, I.-K., Park, G.-H., Lee, K.-M., Schedin, P., and Min, B.-H. (2011). Clusterin induces matrix metalloproteinase-9 expression via ERK1/2 and PI3K/Akt/NF-κB pathways in monocytes/macrophages. Journal of Leukocyte Biology 90, 761-769. Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J Clin 62, 10-29. Sier, C. F., Kubben, F. J., Ganesh, S., Heerding, M. M., Griffioen, G., Hanemaaijer, R., van Krieken, J. H., Lamers, C. B., and Verspaget, H. W. (1996). Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74, 413-417. Sternlicht, M. D., and Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17, 463-516. Streuli, C. (1999). Extracellular matrix remodelling and cellular differentiation. Curr Opin Cell Biol 11, 634-640. Suh, S.-J., Kwak, C.-H., Song, K.-H., Kwon, K.-M., Chung, T.-W., Cho, S.-H., Kim, Y.-K., Yoon, H.-D., Lee, Y.-C., Kim, D.-S., et al. (2012). Triple Inhibitory Activity of <i>Cliona celata</i> Against TNF-α-Induced Matrix Metalloproteinase-9 Production Via Downregulated NF-κB and AP-1, Enzyme Activity, and Migration Potential. Inflammation 35, 736-745. Symowicz, J., Adley, B. P., Gleason, K. J., Johnson, J. J., Ghosh, S., Fishman, D. A., Hudson, L. G., and Stack, M. S. (2007). Engagement of Collagen-Binding Integrins Promotes Matrix Metalloproteinase-9–Dependent E-Cadherin Ectodomain Shedding in Ovarian Carcinoma Cells. Cancer Research 67, 2030-2039. Szabo, R., and Bugge, T. H. (2008). Type II transmembrane serine proteases in development and disease. Int J Biochem Cell B 40, 1297-1316. Takeuchi, T., Shuman, M. A., and Craik, C. S. (1999). Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A 96, 11054-11061. Tanimoto, H., Underwood, L. J., Wang, Y., Shigemasa, K., Parmley, T. H., and O'Brien, T. J. (2001). Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 22, 104-114. Tarin, D. (1985). Clinical and experimental studies on the biology of metastasis. Biochim Biophys Acta 780, 227-235. TSUI, K.-H., CHANG, P.-L., FENG, T.-H., CHUNG, L.-C., SUNG, H.-C., and JUANG, H.-H. (2008). Evaluating the Function of Matriptase and N-Acetyl-glucosaminyltransferase V in Prostate Cancer Metastasis. Anticancer Research 28, 1993-1999. Uhland, K. (2006). Matriptase and its putative role in cancer. Cellular and Molecular Life Sciences 63, 2968-2978. Wang, G., Guo, Q., Hossain, M., Fazio, V., Zeynalov, E., Janigro, D., Mayberg, M. R., and Namura, S. (2009). Bone marrow-derived cells are the major source of MMP-9 contributing to blood–brain barrier dysfunction and infarct formation after ischemic stroke in mice. Brain Research 1294, 183-192. Wenzel, S. E., Balzar, S., Cundall, M., and Chu, H. W. (2003). Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: Association with asthma severity, neutrophilic inflammation, and wound repair. Journal of Allergy and Clinical Immunology 111, 1345-1352. Wiesner, C., Bonfil, R. D., Dong, Z., Yamamoto, H., Nabha, S. M., Meng, H., Saliganan, A., Sabbota, A., and Cher, M. L. (2007). Heterogeneous Activation of MMP-9 Due to Prostate Cancer-Bone Interaction. Urology 69, 795-799. Wu, S.-R., Cheng, T.-S., Chen, W.-C., Shyu, H.-Y., Ko, C.-J., Huang, H.-P., Teng, C.-H., Lin, C.-H., Johnson, M. D., Lin, C.-Y., and Lee, M.-S. (2010). Matriptase Is Involved in ErbB-2-Induced Prostate Cancer Cell Invasion. The American Journal of Pathology 177, 3145-3158. Yan, C., and Boyd, D. D. (2007). Regulation of matrix metalloproteinase gene expression. Journal of Cellular Physiology 211, 19-26. Yu, F., Jiang, Q., Zhou, Y., Yang, Z., Yu, X., Wang, H., Liu, Z., Wang, L., Fang, W., and Guo, S. (2012). Abnormal expression of matrix metalloproteinase-9 (MMP9) correlates with clinical course in Chinese patients with endometrial cancer. Dis Markers 32, 321-327. Zeng, L., Cao, J., and Zhang, X. (2005). Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 11, 6202-6207. Zhang, L., Shi, J., Feng, J., Klocker, H., Lee, C., and Zhang, J. (2004). Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 7, 327-332. Zhang, Y., Cai, X., Schlegelberger, B., and Zheng, S. (1998). Assignment1 of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24-->q25 by in situ hybridization. Cytogenet Cell Genet 83, 56-57. ZHENG, H., TAKAHASHI, H., MURAI, Y., CUI, Z., NOMOTO, K., NIWA, H., TSUNEYAMA, K., and TAKANO, Y. (2006). Expressions of MMP-2, MMP-9 and VEGF are Closely Linked to Growth, Invasion, Metastasis and Angiogenesis of Gastric Carcinoma. Anticancer Research 26, 3579-3583. 中華民國行政院衛生署 (2011). 100年國內主要癌症死因統計. In, (台北: 中華民國行政院衛生署). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64295 | - |
dc.description.abstract | 攝護腺癌在台灣有逐年提升的趨勢,高居男性癌症死亡率中的第七位。一般來說,癌細胞轉移是造成癌症病人死亡的主要原因。癌細胞的轉移過程中,常伴隨著蛋白酶活性的提升,進而促進細胞間質的降解,使得癌細胞得以轉移至其它組織生長。近年來的研究指出,屬於第二型嵌膜絲胺酸蛋白酶的間質蛋白酶,參與各種癌症的惡化過程。然而,間質蛋白酶如何促進攝護腺癌細胞侵襲及惡化的分子機制目前仍未清楚。為了釐清間質蛋白酶在攝護腺癌細胞惡化中的角色,我們建立了具高侵襲能力的攝護腺癌細胞模式,並發現間質蛋白酶及基質金屬第九蛋白酶的表現量會隨著細胞的侵襲能力提升而隨之增加。為了進一步探討間質蛋白酶是否對基質金屬第九蛋白酶的表現或活性有所調控,我們在 PC-3 細胞中,利用質體轉殖方式送入間質蛋白酶使其表現增加,我們研究觀察到基質金屬第九蛋白酶表現量及其活性,會隨著間質蛋白酶活性態提高而增加。且利用單點突變方式證明,間質蛋白酶的活性對於基質金屬第九蛋白酶的調控十分重要。此外,利用核酸干擾技術壓抑間質蛋白酶的表現後,也觀察到基質金屬第九蛋白酶的活性減少。整體來說,在癌症惡化過程中,間質蛋白酶的增加,可能進一步經由活化基質金屬第九蛋白酶,以促進癌細胞的轉移惡化。 | zh_TW |
dc.description.abstract | The main cause of prostate cancer patient death is due to cancer metastasis. During metastasis, invading cells often up-regulate pericellular proteases to degrade extracellular matrix (ECM). Matriptase, a membrane-anchored serine protease, is thought to be involved in tumor progression. However, the detailed molecular mechanisms in which matriptase promotes prostate cancer progression and invasion are still unclear. To clarify the roles of matriptase in prostate cancer progression, we established a prostate cancer PC-3 cell progression model by serially isolating highly invasive cancer cells using matrigel-coated Boyden chambers. In this progression model, the expression and activated levels of matriptase and matrix metalloproteinase 9 (MMP-9) were increased following the cancer progression and correlated with cancer cell invasion. To further analyze whether matriptase can induce the expression or gelatinolytic activity of MMP-9, we performed overexpression experiments to increase the activated level of matripase in PC-3 cells and found that matriptase overexpression induced MMP-9 gelatinolytic activity and expression, while a catalytically inactive mutant of matriptase (S805A) had no significant effect on the biological events. Moreover, matriptase knockdown by siRNA to down-regulate MMP-9 activity. Taken together, the data indicated that these increase levels of activated matriptase following the progression of prostate cancer cells was involved in up-regulating MMP-9 and promoting cancer cell invasion. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T17:39:16Z (GMT). No. of bitstreams: 1 ntu-101-R99442005-1.pdf: 8600741 bytes, checksum: f6eb6270d58790036e36d69a1e3f2fc4 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 致謝 i
摘要 iii Abstract iv Contents I List of Figures II Chapter 1. Introduction 1 1.1 Prostate cancer 1 1.2 Type II transmembrane serine proteases (TTSPs) 2 1.3 Matriptase 3 1.4 Activation of matriptase 4 1.5 Matrix metalloproteinases (MMPs) 7 1.6 Matrix metalloproteinases 9 (MMP-9) 9 1.7 Research motivation 10 Chapter 2. Materials and methods 12 2.1 Materials 12 2.2 Methods 16 2.3 Buffers 26 Chapter 3. Results 27 3.1 Up-regulation of matriptase and MMP-9 in PC-3 cell progression model. 27 3.2 Roles of MMPs in PC-3 cell motility. 28 3.3 Role of matriptase in the activities of MMP-2 and -9 in PC-3 cells. 29 3.4 Effect of matriptase overexpression in low matriptase-expressed PC-3 cells. 30 3.5 Effect of matriptase and its protease-null mutant (S805A) on MMP-9 in PC-3 cells. 30 3.6 Effect of matriptase overexpression on MMP-2 and -9 in other prostate cancer cells. 32 3.7 Involvement of Akt and NF-κB signaling in matriptase-induced MMP-9 gelatinolytic activity in PC-3 cells. 32 Chapter 4. Discussion 34 Chapter 5. Figures 39 Chapter 6. References 60 | |
dc.language.iso | en | |
dc.title | 探討間質蛋白酶在攝護腺癌細胞中對細胞基質第九金屬蛋白酶之影響 | zh_TW |
dc.title | Matriptase induced the expression and activation of matrix metalloproteinase 9 (MMP-9) in human prostate cancer PC-3 cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 呂紹俊,李明亭,黃娟娟,王正康 | |
dc.subject.keyword | 攝護腺癌,間質蛋白酶,基質金屬第九蛋白酶,癌症惡化,細胞運動, | zh_TW |
dc.subject.keyword | prostate cancer,matriptase,matrix metalloproteinase 9,cancer progression,cell motility, | en |
dc.relation.page | 68 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 8.4 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。